The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Tuberculosis drug discovery in the post‐post‐genomic era
Open accessAbstract
The expectation that genomics would result in new therapeutic interventions for infectious diseases remains unfulfilled. In the post‐genomic era, the decade immediately following the availability of the genome sequence of M ycobacterium tuberculosis , tuberculosis ( TB ) drug discovery relied heavily on the target‐based approach but this proved unsuccessful leading to a return to whole cell screening. Genomics underpinned screening by providing knowledge and many enabling technologies, most importantly whole genome resequencing to find resistance mutations and targets, and this resulted in a selection of leads and new TB drug candidates that are reviewed here. Unexpectedly, many new targets were found to be ‘promiscuous’ as they were inhibited by a variety of different compounds. In the post‐post‐genomics era, more advanced technologies have been implemented and these include high‐content screening, screening for inhibitors of latency, the use of conditional knock‐down mutants for validated targets and si RNA screens. In addition, immunomodulation and pharmacological manipulation of host functions are being explored in an attempt to widen our therapeutic options.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence
Cole, S. T., Brosch, R., Parkhill, J., Garnier, T., Churcher, C., Harris, D., Gordon, S. V., Eiglmeier, K., Gas, S., Barry, C. E., et al. (1998) · Nature · doi:10.1038/31159 · Cited by 7,847
Self-citationGenes required for mycobacterial growth defined by high density mutagenesis
Sassetti, C. M., Boyd, D. H., & Rubin, E. J. (2003) · Molecular Microbiology · doi:10.1046/j.1365-2958.2003.03425.x · Cited by 2,544 · cited 1×
“…many of the targets that were validated as being essential in vitro by genetic means, such as gene replacement or saturation transposon mutagenesis (Sassetti et al , 2003), proved not to be required during infection due to genetic redundancy or metabolic scavenging, leading us to appreciate that…”
Drugs for bad bugs: confronting the challenges of antibacterial discovery
Payne, D. J., Gwynn, M. N., Holmes, D. J., & Pompliano, D. L. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2201 · Cited by 2,512
A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis
Andries, K., Verhasselt, P., Guillemont, J., Göhlmann, H. W. H., Neefs, J.-M., Winkler, H., Van Gestel, J., Timmerman, P., Zhu, M., Lee, E., et al. (2005) · Science · doi:10.1126/science.1106753 · Cited by 2,191 · cited 1×
“In 2005, using a classical phenotypic screen, Andries et al (2005) discovered a very potent molecule, TMC207 or bedaquiline, an innovative, recently-approved drug candidate that offers considerable hope for curing MDR-TB cases.”
inhA , a Gene Encoding a Target for Isoniazid and Ethionamide in Mycobacterium tuberculosis
Banerjee, A., Dubnau, E., Quemard, A., Balasubramanian, V., Um, K. S., Wilson, T., Collins, D., de Lisle, G., & Jacobs, W. R. (1994) · Science · doi:10.1126/science.8284673 · Cited by 1,389 · cited 1×
“Ethionamide (ETH) is an approved second-line drug but with considerable side effects (Weinstein et al , 1962) that inhibits the enoyl-ACP reductase, InhA, the target of isoniazid (INH), thus preventing mycolic acid synthesis (Banerjee et al , 1994).”
Benzothiazinones Kill Mycobacterium tuberculosis by Blocking Arabinan Synthesis
Makarov, V., Manina, G., Mikusova, K., Möllmann, U., Ryabova, O., Saint-Joanis, B., Dhar, N., Pasca, M. R., Buroni, S., Lucarelli, A. P., et al. (2009) · Science · doi:10.1126/science.1171583 · Cited by 740 · cited 1×
“Benzothiazinones (BTZ), a new class of sulphur containing heterocyclic compounds, are extremely potent against Mtb , displaying low nanomolar bactericidal activity in vitro and in intracellular infection models (Makarov et al , 2009).”
Self-citationRoca, F. J., & Ramakrishnan, L. (2013) · Cell · doi:10.1016/j.cell.2013.03.022 · Cited by 592
Inhibition of mycolic acid transport across the Mycobacterium tuberculosis plasma membrane
Grzegorzewicz, A. E., Pham, H., Gundi, V. A. K. B., Scherman, M. S., North, E. J., Hess, T., Jones, V., Gruppo, V., Born, S. E. M., Korduláková, J., et al. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.794 · Cited by 442 · cited 4×
“Interestingly, many other MmpL3 inhibitors have been found and amongst these are the adamantyl urea compound (AU1235), which is structurally related to SQ109 (Grzegorzewicz et al , 2012), and the benzimidazole C215 (Stanley et al , 2012).”
InfluentialIdentification of Novel Imidazo[1,2-a]pyridine Inhibitors Targeting M. tuberculosis QcrB
Abrahams, K. A., Cox, J. A. G., Spivey, V. L., Loman, N. J., Pallen, M. J., Constantinidou, C., Fernández, R., Alemparte, C., Remuiñán, M. J., Barros, D., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0052951 · Cited by 177 · cited 3×
“Using this system, Abrahams et al generated conditional Mtb knock-down mutants of the essential panC gene, which encodes pantothenate synthase (Abrahams et al , 2012a).”
Cited by
Wassermann, R., Gulen, M. F., Sala, C., Perin, S. G., Lou, Y., Rybniker, J., Schmid-Burgk, J. L., Schmidt, T., Hornung, V., Cole, S. T., et al. (2015) · Cell Host & Microbe · doi:10.1016/j.chom.2015.05.003 · Cited by 401
“Tuberculosis (TB) is a major cause of morbidity and mortality worldwide (Lechartier et al., 2014).”
BackgroundSelf-citationMycobacterium tuberculosis infection of host cells in space and time
Bussi, C., & Gutierrez, M. G. (2019) · FEMS Microbiology Reviews · doi:10.1093/femsre/fuz006 · Cited by 344
New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects
Zumla, A. I., Gillespie, S. H., Hoelscher, M., Philips, P. P. J., Cole, S. T., Abubakar, I., McHugh, T. D., Schito, M., Maeurer, M., & Nunn, A. J. (2014) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70328-1 · Cited by 342
Self-citationChemotherapy of leishmaniasis: present challenges
ULIANA, S. R. B., TRINCONI, C. T., & COELHO, A. C. (2018) · Parasitology · doi:10.1017/s0031182016002523 · Cited by 261
Lansoprazole is an antituberculous prodrug targeting cytochrome bc1
Rybniker, J., Vocat, A., Sala, C., Busso, P., Pojer, F., Benjak, A., & Cole, S. T. (2015) · Nature Communications · doi:10.1038/ncomms8659 · Cited by 191
Self-citation
Metadata
- Authors
- Lechartier, B., Rybniker, J., Zumla, A., & Cole, S. T.
- Venue
- EMBO Molecular Medicine
- Published
- 2014-01-08
- Volume
- 6
- Issue
- 2
- Pages
- 158-168
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- OpenAlex
- W2122267877
- Cited by
- 176
- References
- 9
- FWCI
- 17.09
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.